USPTO serial 87040256
POWDERHALE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 11, 2017
- Examiner
- VOHRA, SANJEEV KUMAR
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with POWDERHALE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Chippenham, Wiltshire, GB
Chippenham, Wiltshire, GB
Chippenham, Wiltshire, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark Harrison
MARK HARRISON VENABLE LLPP.O. BOX 34385WASHINGTON, DC 20043-9998UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system; pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for the alleviation or prevention of pain or inflammation; inhalers filled with powders for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical preparations, namely, powders for asthma inhalers; pharmaceutical preparations, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for erectile dysfunction; pharmaceutical and veterinary preparations for chronic obstructive pulmonary disease; pharmaceutical and veterinary preparations for premature ejaculation; pharmaceutical and veterinary preparations for cystic fibrosis; pharmaceutical and veterinary preparations for female sexual dysfunction; medicaments for migraine; pharmaceutical and veterinary preparations for asthma | SECTION 8 - CANCELLED | — |
| 010 | Inhalers for medical purposes, sold empty; metered dose inhalers for medical purposes, sold empty; active dry powder inhalers for medical purposes, sold empty; passive dry powder inhalers for medical purposes, sold empty; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goods | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 26, 2024 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jul 11, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jul 11, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 25, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 25, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 5, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 18, 2017 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Feb 24, 2017 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Feb 24, 2017 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Feb 22, 2017 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Feb 16, 2017 | ERTI | TEAS RESPONSE TO PETITION INQUIRY LETTER | — |
| Feb 13, 2017 | PILM | PETITION INQUIRY LETTER ISSUED | — |
| Feb 8, 2017 | APET | ASSIGNED TO PETITION STAFF | — |
| Feb 8, 2017 | 44EP | 44(e) PETITION - RECEIVED | — |
| Jan 21, 2017 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 21, 2016 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Dec 13, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 18, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 18, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 28, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 12, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 1, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 1, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 1, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 1, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 1, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 31, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 14, 2016 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jul 8, 2016 | ALIE | ASSIGNED TO LIE | — |
| Jul 1, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| May 24, 2016 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| May 23, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 20, 2016 | NWAP | NEW APPLICATION ENTERED | — |